Samsung Biologics Extends Manufacturing Deal with BMS


CDMO will continue to produce commercial antibody cancer drug substance, featuring a new $242 million agreement.

Various viruses, microbes and bacteria, types of microorganisms under microscopic magnification. Macro.Generative AI illustration. Microbiology. Image Credit: Adobe Stock Images/Anastasia

Image Credit: Adobe Stock Images/Anastasia

Samsung Biologics, a contract development and manufacturing organization (CDMO), has reached a new $242 million deal with Bristol Myers Squibb (BMS) for large-scale manufacturing of a BMS commercial antibody cancer drug substance.

BMS and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic relationship over time. Per the terms of the new agreement, the CDMO is expected to provide drug substance manufacturing for an antibody cancer drug substance at the company’s latest and largest biomanufacturing facility, Plant 4, in Songdo, South Korea.

“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” says John Rim, president and CEO of Samsung Biologics. “This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity.”

Related Videos
© 2024 MJH Life Sciences

All rights reserved.